4.7 Article

Variation in detection of ductal carcinoma in situ during screening mammography: A survey within the International Cancer Screening Network

Journal

EUROPEAN JOURNAL OF CANCER
Volume 50, Issue 1, Pages 185-192

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2013.08.013

Keywords

Breast cancer; Ductal carcinoma in situ (DCIS); Screening mammography; Cancer registration

Categories

Funding

  1. National Cancer Institute [U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA 70013, U01CA69976, U01CA63731, U01CA70040]
  2. NATIONAL CANCER INSTITUTE [U01CA070013, U01CA086076, U01CA086082, U01CA063731, U01CA063740, U01CA070040, U01CA069976, U01CA063736] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Background: There is concern about detection of ductal carcinoma in situ (DCIS) in screening mammography. DCIS accounts for a substantial proportion of screen-detected lesions but its effect on breast cancer mortality is debated. The International Cancer Screening Network conducted a comparative analysis to determine variation in DCIS detection. Patients and Methods: Data were collected during 2004-2008 on number of screening examinations, detected breast cancers, DCIS cases and Globocan 2008 breast cancer incidence rates derived from national or regional cancer registers. We calculated screen-detection rates for breast cancers and DCIS. Results: Data were obtained from 15 screening settings in 12 countries; 7,176,050 screening examinations; 29,605 breast cancers and 5324 DCIS cases. The ratio between highest and lowest breast cancer incidence was 2.88 (95% confidence interval (CI) 2.76-3.00); 2.97 (95% CI 2.51-3.51) for detection of breast cancer; and 3.49 (95% CI 2.70-4.51) for detection of DCIS. Conclusions: Considerable international variation was found in DCIS detection. This variation could not be fully explained by variation in incidence nor in breast cancer detection rates. It suggests the potential for wide discrepancies in management of DCIS resulting in overtreatment of indolent DCIS or undertreatment of potentially curable disease. Comprehensive cancer registration is needed to monitor DCIS detection. Efforts to understand discrepancies and standardise management may improve care. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available